RecruitingPhase 2NCT03993262
Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis
Studying Autoimmune encephalitis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jena University Hospital
- Principal Investigator
- Christian Geis, Prof.University Hospital Jena
- Intervention
- Bortezomib(drug)
- Enrollment
- 50 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (17)
- Ludwig-Maximilians-Universität München, Klinikum Großhadern, München, Bavaria, Germany
- Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
- Universitätsklinikum Jena, Sektion Translationale Neuroimmunologie, Klinik für Neurologie, Jena, Germany, Germany
- Medizinische Hochschule Hannover, Hanover, Niedersachen, Germany
- Charité - Universitätsmedizin Berlin, Klinik für Neurologie mit Experimenteller Neurologie, Berlin, Germany
- Ruhr-Universität Bochum, St. Josef Hospital, Klinik für Neurologie, Bochum, Germany
- University Hospital Düsseldorf, Clinic for Neurology, Düsseldorf, Germany
- Universitätsklinikum Erlangen, Neurologische Klinik, Erlangen, Germany
- Universitätsklinikum Essen (AöR), Klinik für Neurologie, Essen, Germany
- University Hospital Frankfurt (Main), Clinic for Neurology, Frankfurt, Germany
- Universitätsmedizin Göttingen Georg-August-Universität, Klinik für Neurologie, Göttingen, Germany
- Universitätsmedizin Greifswald, Klinik und Poliklinik für Neurologie, Greifswald, Germany
- Klinik für Neurologie UKSH, Campus Kiel, Kiel, Germany
- Universitätsklinikum Leipzig, Klinik und Poliklinik für Neurologie, Leipzig, Germany
- Universitätsmedizin Mainz, Klinik und Poliklinik für Neurologie, Mainz, Germany
- +2 more locations on ClinicalTrials.gov
Collaborators
Federal Ministry of Education and Reserach (BMBF)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03993262 on ClinicalTrials.govOther trials for Autoimmune encephalitis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07158229Long-term Impact of NMDAR Encephalitis, Level 3Hospices Civils de Lyon
- RECRUITINGNCT07477015Study of Pathogenic Mechanisms and Identification of Novel Autoantibodies in Autoimmune EncephalitisFondazione Policlinico Universitario Agostino Gemelli IRCCS
- RECRUITINGPHASE3NCT06867991Safety and Efficacy of Combined B Cell Depleting theRapy And Daratumumab In Autoimmune EncephalitisThe First People's Hospital of Changzhou
- RECRUITINGNANCT06584045Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis)Tongji Hospital
- RECRUITINGNCT07133113Medium-term Effects of Treatments in Autoimmune EncephalitisHospices Civils de Lyon
- RECRUITINGNCT06019975FDG-PET in the Diagnosis of Autoimmune EncephalitisUniversity of Milano Bicocca
- RECRUITINGPHASE3NCT05503264A Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Satralizumab in Participants With Anti-N-methyl-D-aspartic Acid Receptor (NMDAR) or Anti-leucine-rich Glioma-inactivated 1 (LGI1) EncephalitisHoffmann-La Roche
- ACTIVE NOT RECRUITINGNCT07145502Monitoring of Outcomes of Cellular and Exosome-based Therapies in Autoinflammatory and Post-infectious Neuroinflammatory SyndromesBiocells Medical